Frontiers in Immunology (Feb 2024)
Immune checkpoint ligands expressed on mature high endothelial venules predict poor prognosis of NSCLC: have a relationship with CD8+ T lymphocytes infiltration
- Jing Luo,
- Jing Luo,
- Jing Luo,
- Jing Luo,
- Xiuhuan Shi,
- Xiuhuan Shi,
- Xiuhuan Shi,
- Xiuhuan Shi,
- Xiuhuan Shi,
- Yumeng Liu,
- Yumeng Liu,
- Yumeng Liu,
- Yumeng Liu,
- Jian Wang,
- Jian Wang,
- Jian Wang,
- Jian Wang,
- Hao Wang,
- Hao Wang,
- Hao Wang,
- Hao Wang,
- Hao Wang,
- Xuena Yang,
- Xuena Yang,
- Xuena Yang,
- Xuena Yang,
- Qian Sun,
- Qian Sun,
- Qian Sun,
- Qian Sun,
- Qian Sun,
- Zhenzhen Hui,
- Zhenzhen Hui,
- Zhenzhen Hui,
- Zhenzhen Hui,
- Feng Wei,
- Feng Wei,
- Feng Wei,
- Feng Wei,
- Feng Wei,
- Xiubao Ren,
- Xiubao Ren,
- Xiubao Ren,
- Xiubao Ren,
- Xiubao Ren,
- Xiubao Ren,
- Hua Zhao,
- Hua Zhao,
- Hua Zhao,
- Hua Zhao,
- Hua Zhao
Affiliations
- Jing Luo
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
- Jing Luo
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Jing Luo
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Jing Luo
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xiuhuan Shi
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
- Xiuhuan Shi
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Xiuhuan Shi
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Xiuhuan Shi
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xiuhuan Shi
- Department of Medical Oncology, Affiliated Hospital of Inner Mongolia Medical University, Huhhot, China
- Yumeng Liu
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
- Yumeng Liu
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Yumeng Liu
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Yumeng Liu
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Jian Wang
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
- Jian Wang
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Jian Wang
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Jian Wang
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Hao Wang
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
- Hao Wang
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Hao Wang
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Hao Wang
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Hao Wang
- The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China
- Xuena Yang
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
- Xuena Yang
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Xuena Yang
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Xuena Yang
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Qian Sun
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
- Qian Sun
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Qian Sun
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Qian Sun
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Qian Sun
- Haihe Laboratory of Cell Ecosystem, Tianjin, China
- Zhenzhen Hui
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
- Zhenzhen Hui
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Zhenzhen Hui
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Zhenzhen Hui
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Feng Wei
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
- Feng Wei
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Feng Wei
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Feng Wei
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Feng Wei
- Haihe Laboratory of Cell Ecosystem, Tianjin, China
- Xiubao Ren
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
- Xiubao Ren
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Xiubao Ren
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Xiubao Ren
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xiubao Ren
- Haihe Laboratory of Cell Ecosystem, Tianjin, China
- Xiubao Ren
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Hua Zhao
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
- Hua Zhao
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Hua Zhao
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Hua Zhao
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Hua Zhao
- Haihe Laboratory of Cell Ecosystem, Tianjin, China
- DOI
- https://doi.org/10.3389/fimmu.2024.1302761
- Journal volume & issue
-
Vol. 15
Abstract
BackgroundAn insufficient number of intratumoral CD8+ T lymphocytes is a major barrier to antitumor immunity and immunotherapy. High endothelial venules (HEVs) are the major sites through which lymphocytes enter tumors; however, the molecular mechanism through which HEVs mediate CD8+ T lymphocyte infiltration remains poorly understood.MethodsForty-two patients with stage IIIA lung adenocarcinoma, who underwent surgery, were recruited. Multiplex immunohistochemical staining was conducted on tumor tissues to detect the immune checkpoint ligands (ICLs) expressed in the HEVs, blood vessels, and lymphatics. A new ICL score model was constructed to evaluate ligand expression. The relationship between ICL score, tumor-infiltrating CD8+ T cell frequency, and survival of patients was investigated.ResultsMature HEVs, but not blood vessels or lymphatics, mediated CD8+ T cell infiltration. However, the ICLs expressed on mature HEVs could negatively regulate CD8+ T cell entry into tertiary lymphoid structures (TLSs). In addition, according to the results obtained using our ICLtotal score model, the expression of ICLs on HEVs was observed to be a predictor of both CD8+ T cell infiltration and survival, in which a high ICLtotal score > 1 represent a weak CD8+ T cell infiltration and a high ICLtotal score > 2 predicts poor survival.ConclusionUsing the ICL score model, we discovered that ICLs expressed on HEVs are indicative of CD8+ T cell subset infiltration in TLSs, as well as of patient survival with lung cancer.
Keywords
- lung cancer
- immune checkpoint ligands
- high endothelial venules
- lymphocytes infiltration
- tertiary lymphoid structures